Bronchogen is a four-amino-acid peptide from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology. The defining patent and most of the group's papers give the sequence as Ala-Glu-Asp-Leu (AEDL).
Bronchogen Prices
7 vendors · 0 with an issuer-verified COA · lowest 10mg from $43.99 · checked
Where to buy Bronchogen: 7 vendors compared
| Vendor | Price | Actions |
|---|---|---|
| $43.99 | Buy Bronchogen from Cenexa Labs | |
| $44.99 | Buy Bronchogen from MS Peptides | |
| $52.20 | Buy Bronchogen from Ameano Peptides | |
| $52.20 | Buy Bronchogen from EZ Peptides | |
| $53.4420mg packageChecked today | Buy Bronchogen from Regenix Peptides | |
| $55.24 | Buy Bronchogen from SomaChems | |
| $62.97 | Buy Bronchogen from BioLongevity Labs |
Tracked every day
Bronchogen listing prices, tracked daily
The five cheapest in-stock package prices for Bronchogen on each collected day, and the vendors that most often held those places.
No collected listings for this compound yet.
Current market data
Bronchogen Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Bronchogen is $43.99 from Cenexa Labs. The median across vendors is $52.20.
- Lowest 10mg cost
- $43.99Cenexa Labs
- Median 10mg cost
- $52.20One normalized offer per vendor
- Lowest package total
- $43.99Cenexa Labs · package size may differ
- Public COA coverage
- 100%7 of 7 vendors
What the market shows
PeptidePrices found 7 in-stock listings from 7 vendors, checked through Oct 8, 2026. The lowest 10mg cost is 16% below the vendor median of $52.20; 2 vendors (29%) fall below that median. 7 of 7 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Bronchogen? Research, safety, and status
Bronchogen is a synthetic tetrapeptide: alanine, glutamic acid, aspartic acid, leucine. At about 446 Da it is tiny. The Khavinson group's position is that peptides this short enter the cell nucleus, bind DNA or histone proteins at specific sites, and push gene expression back toward a younger pattern. For Bronchogen, they also report test-tube binding to wheat histones.
The sequence question has a clear answer on paper, with one open end. The US patent filed by Khavinson and co-inventors in 2004 claims Ala-Glu-Asp-Leu. PubChem's "Bronchogen" record resolves to the same order. The group's 2012 differentiation paper, its 2013 histone paper, its 2021 systematic review and its 2023 transporter-docking paper all write AEDL. Two papers write Ala-Asp-Glu-Leu instead: the 2011 DNA thermostability study names "bronchogen (Ala-Asp-Glu-Leu)" in its title, and the 2014 Lung paper calls the peptide ADEL throughout, labels its figures "Bronchogen," and cites the AEDL patent for the compound's earlier animal results.
Key research takeaways
Two of the group's own papers (2011 and 2014) print it as Ala-Asp-Glu-Leu (ADEL), while describing the same compound and citing the AEDL patent. The two orders have exactly the same mass, so a routine mass check cannot tell them apart.
The strongest published work is a pair of rat COPD-model studies from a separate St. Petersburg pulmonology institute. They report less airway remodeling and inflammation. The abstracts give no group sizes and no sequence.
Everything else is cell culture, test-tube DNA chemistry and patent examples. We found no human trial and no lab outside Russia and Georgia that has tested it.
Vendor pages get the details wrong in places. One describes the NO2 COPD study as a mouse study; it was in rats.
Bronchogen at a glance
PeptidePrices safety rating
6/10 · Not FDA-approved
Mechanism
Proposed bioregulator of bronchial epithelium; cell and rat studies report effects on differentiation markers and DNA binding.
Research areas
Bronchial and lung-tissue bioregulator research. Human clinical benefit is not established.
Regulatory / research status
Research / preclinical only
Half-life
Not established in direct human pharmacokinetic studies.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
Human safety data is sparse. The available evidence is mainly preclinical and small Russian studies from one research group, and it does not establish clinical efficacy.
Russian bioregulator; short peptide; limited but clean data. Human evidence is thin and mostly from one research group. Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- Bronchogen is a four-amino-acid peptide from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology. The defining patent and most of the group's papers give the sequence as Ala-Glu-Asp-Leu (AEDL).
- Two of the group's own papers (2011 and 2014) print it as Ala-Asp-Glu-Leu (ADEL), while describing the same compound and citing the AEDL patent. The two orders have exactly the same mass, so a routine mass check cannot tell them apart.
- The strongest published work is a pair of rat COPD-model studies from a separate St. Petersburg pulmonology institute. They report less airway remodeling and inflammation. The abstracts give no group sizes and no sequence.
- Everything else is cell culture, test-tube DNA chemistry and patent examples. We found no human trial and no lab outside Russia and Georgia that has tested it.
Selected references
- Peptide substance restoring respiratory organs function · patents.google.com, 2004
- PubChem. Bronchogen, CID 11690869. National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov
- Peptides tissue-specifically stimulate cell differentiation during their aging · PubMed, 2012
- RLS Encyclopedia · rlsnet.ru
- Peptide regulation of gene expression: a systematic review · PubMed, 2021
- Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides · PubMed, 2013
Related pages